Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced NSCLC”

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05048797
What this trial is testing

Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 454
Large-scale testing (Phase 3)Study completedNCT00478049
What this trial is testing

Iressa as Second Line Therapy in Advanced NSCLC-Asia

Who this might be right for
NSCLC
AstraZeneca 163
Large-scale testing (Phase 3)Active Not RecruitingNCT06151574
What this trial is testing

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Who this might be right for
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim 428
Large-scale testing (Phase 3)Not Yet RecruitingNCT07376382
What this trial is testing

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 680
Testing effectiveness (Phase 2)UnknownNCT01203735
What this trial is testing

Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer

Who this might be right for
Locally Advanced Inoperable Non-small-lung Cancer
Soroka University Medical Center 20
Large-scale testing (Phase 3)Ended earlyNCT01377376
What this trial is testing

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT07070440
What this trial is testing

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Who this might be right for
Non Small Cell Lung Cancer
Dizal Pharmaceuticals 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Early research (Phase 1)Study completedNCT04858958
What this trial is testing

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 90
Testing effectiveness (Phase 2)Study completedNCT00075426
What this trial is testing

Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
The University of Texas Medical Branch, Galveston 30
Not applicableStudy completedNCT03559647
What this trial is testing

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche 358
Testing effectiveness (Phase 2)Looking for participantsNCT07730021
What this trial is testing

ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc. 392
Large-scale testing (Phase 3)Study completedNCT01953913
What this trial is testing

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 542
Not applicableActive Not RecruitingNCT05721950
What this trial is testing

Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT05635708
What this trial is testing

Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
BeiGene 400
Large-scale testing (Phase 3)Study completedNCT00257608
What this trial is testing

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 1,145
Large-scale testing (Phase 3)Study completedNCT03735121
What this trial is testing

Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 438
Early research (Phase 1)Study completedNCT01059552
What this trial is testing

Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Locally Advanced Non-small Cell Lung Cancer
Fox Chase Cancer Center 18
Testing effectiveness (Phase 2)Ended earlyNCT02275806
What this trial is testing

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Who this might be right for
Lung Neoplasms, Non-Small Cell Lung Cancer
Leo W. Jenkins Cancer Center 4
Large-scale testing (Phase 3)UnknownNCT02387086
What this trial is testing

Gefitinib Combined With Thalidomide to Treat NSCLC

Who this might be right for
NSCLC
Bai Jun 380
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation